A new approach for treatment of atherosclerosis and plaque stabilization
Figure: Crystallographic structure of a small-molecule ligand binding the catalytic domain of PFKFB3.
Atherosclerosis is the leading cause of heart attacks, stroke and vascular disease. It consists in the thickening, clogging and hardening of arteries caused by the accumulation of white blood cells in certain regions of arteries, which in turn causes their inflammation and blood flow obstruction. The underpinning scientific idea in MOGLYNET is to exploit the modulation of glycolytic flux - a fundamental metabolic pathway that is critical for the production of energy in living organisms - as a new approach for the treatment of atherosclerosis and plaque stabilization.
Funded by the European Commission (H2020 Marie Skłodowska-Curie ITN-European Joint Doctorate)
Website: http://www.moglynet.com
Project team:
Professor Matteo Zanda (Research scientist, University of Aberdeen)
Professor Mirela Delibegovic (Research scientist, University of Aberdeen)
Dr Sergio Dall’Angelo (Research scientist, University of Aberdeen)